Education
About Us
Working with TipRanks
Follow Us
Cerus Corp (CERS)
NASDAQ:CERS
CERS Stock Chart & Stats
$2.56
-$0.02(-1.22%)
At close: 4:00 PM EST
$2.56
-$0.02(-1.22%)
Day’s Range― - ―
52-Week Range$1.12 - $2.96
Previous CloseN/A
Volume302.69K
Average Volume (3M)1.09M
Market Cap
$491.74M
Enterprise Value$574.26M
Total Cash (Recent Filing)$78.51M
Total Debt (Recent Filing)$98.19M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Mar 02, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding192,087,500
10 Day Avg. Volume1,337,014
30 Day Avg. Volume1,085,575
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)5.06
Price to Sales (P/S)1.58
P/FCF Ratio33.35
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue2.88
Enterprise Value/Gross Profit5.22
Enterprise Value/Ebitda-97.80
Forecast
1Y Price Target
$5.00Price Target Upside95.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$250.00M
Bulls Say, Bears Say
Bulls Say
Commercial PartnershipsGroup purchasing agreement with Blood Centers of America widens national access to the full product line and leverages established member-center logistics to accelerate distribution and adoption across underpenetrated regions.
Financial And Operational MomentumRecord product revenue accompanied by raised revenue guidance and sustained positive adjusted EBITDA quarters signals improving commercial execution and operational leverage that support growth prospects.
IFC Fibrinogen AdoptionIFC fibrinogen kits are building momentum as clinician advocacy and real-world analyses highlight clinical and economic benefits, supporting increased hospital uptake and a shift toward blood-center kit manufacturing.
Bears Say
Execution And Scaling RiskSuccessful expansion depends on executing training, distributed manufacturing, and coordinated logistics at blood centers, and shortfalls in these areas could impede adoption and throughput.
Independent Blood Center Penetration RiskPenetration within independent blood centers remains relatively low, creating a material risk if expansion efforts fail to convert this large segment into consistent demand.
Share-price SentimentShares have lagged peers and trading near the 52-week low reflects investor skepticism that could intensify downside pressure if growth milestones are missed.
Cerus News
CERS FAQ
What was Cerus Corp’s price range in the past 12 months?
Cerus Corp lowest stock price was $1.12 and its highest was $2.96 in the past 12 months.
What is Cerus Corp’s market cap?
Cerus Corp’s market cap is $491.74M.
When is Cerus Corp’s upcoming earnings report date?
Cerus Corp’s upcoming earnings report date is Mar 02, 2026 which is today.
How were Cerus Corp’s earnings last quarter?
Cerus Corp released its earnings results on Nov 06, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.028 by $0.028.
Is Cerus Corp overvalued?
According to Wall Street analysts Cerus Corp’s price is currently Undervalued.
Does Cerus Corp pay dividends?
Cerus Corp does not currently pay dividends.
What is Cerus Corp’s EPS estimate?
Cerus Corp’s EPS estimate is >-0.01.
How many shares outstanding does Cerus Corp have?
Cerus Corp has 192,087,500 shares outstanding.
What happened to Cerus Corp’s price movement after its last earnings report?
Cerus Corp reported an EPS of $0 in its last earnings report, beating expectations of -$0.028. Following the earnings report the stock price went up 21.277%.
Which hedge fund is a major shareholder of Cerus Corp?
Currently, no hedge funds are holding shares in CERS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cerus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (95.31% Upside)
$5.00 (95.31% Upside)
Blogger Sentiment
Bullish
CERS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.00%
12-Months-Change
Fundamentals
Return on Equity
-27.77%
Trailing 12-Months
Asset Growth
13.53%
Trailing 12-Months
Company Description
Cerus Corp
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
CERS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Cerus Corporation's earnings call for Q3 2025 highlighted significant revenue growth and positive financial performance, driven by strong demand for INTERCEPT products and successful international expansion efforts. However, the company faces challenges with gross margin pressures and regulatory delays in Europe. Despite these hurdles, the overall outlook remains optimistic with raised revenue guidance and continued focus on operational execution.View all CERS earnings summariesCERS Stock 12 Month Forecast
Average Price Target
$5.00
▲(95.31% Upside)
Technical Analysis
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Outset Medical
―
908 Devices
―
Ownership Overview
4.87% Insiders
13.71% Mutual Funds
25.39% Other Institutional Investors
36.32% Public Companies and
Individual Investors